8月3日 - ** Supernus Pharmaceuticals（SUPN.O）股价在盘前交易中上涨16.5%，至52美元
** 该公司将 (link) 与Indivior Pharmaceuticals INDV.O 合并，组建一家专注于中枢神经系统的多元化生物制药公司
** INDV股东将在交易完成前获得总额10亿美元的一次性特别现金股息；SUPN股东将按每股SUPN股份换取1.5401股INDV股份
** 新实体将命名为 Supernus，由 SUPN 现任首席执行官杰克·卡塔尔（Jack Khattar）领导
** 交易预计将于2026年第四季度完成
** 公司公布第二季度营收为2.1906亿美元，超过分析师预估的2.0496亿美元——数据由伦敦证券交易所集团（LSEG）汇总
** 截至上一交易日收盘，该股年内累计下跌10.2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.